In vitro immunization of Epstein-Barr virus-immortalized B cells augments antigen-specific antibody production

Gakuro Harada, Shin Ei Matsumoto, Makiko Yamashita, Kaoru Fujii, Sanetaka Shirahata, Yoshinori Katakura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The current method for in vitro immunization (IVI) uses several antigens including toxins, food allergens, pathogenic bacteria, and self-antigen-derived peptides that induce an antigen-specific immune response in peripheral blood mononuclear cells (PBMCs). This protocol, however, requires donor blood collection and preparation of PBMCs before every IVI. In the present study, we aimed to design a more efficient system utilizing B cells immortalized with Epstein-Barr virus (EBV-B) as host cells for IVI to make antigen-specific antibodies. Results showed that previously antigen-sensitized, EBV-B cells exposed to the antigen along with IL-6, CpG oligonucleotides, and CD40 ligand signal produced antigen-specific antibodies. These results provide evidence for a novel and easy method to expand memory-type B cells and produce antigen-specific antibodies.

Original languageEnglish
Pages (from-to)979-983
Number of pages5
JournalCytotechnology
Volume65
Issue number6
DOIs
Publication statusPublished - Dec 1 2013

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'In vitro immunization of Epstein-Barr virus-immortalized B cells augments antigen-specific antibody production'. Together they form a unique fingerprint.

  • Cite this